$MRNA
Moderna, Inc.
mRNA therapeutics and vaccines pioneer known for COVID-19 vaccine.
MRNA key facts as of November 14, 2026
- Latest AI research report
- MRNA Stock: Costs, Cancer Pipeline and Risks (as of November 14, 2026)
- StockAlpha report sentiment
- Bearish (as of November 14, 2026)
- Analyst consensus
- Hold (1 Strong Buy, 3 Buy, 16 Hold, 2 Sell, 2 Strong Sell) (as of November 1, 2026)
- Analyst price target
- $143.67 mean (range $25.00 to $305.00) (as of November 17, 2026)
- Sector
- Healthcare
Analysis from Nov 13, 2026
MRNA Stock: Costs, Cancer Pipeline and Risks
Moderna reported a Q3 EPS beat and is advancing a planned cancer-therapy filing, but rising cost concerns and uncertain revenue visibility weighed on the shares heading into the weekend. The analyst consensus is Hold, with the supplied mean target 34% below Friday’s closing price.
Previous Reports
MRNA FAQ
What is StockAlpha's latest view on MRNA?
StockAlpha's latest AI research report on Moderna, Inc. (MRNA), "MRNA Stock: Costs, Cancer Pipeline and Risks", was published on November 14, 2026 and rates the overall sentiment as bearish. Moderna reported a Q3 EPS beat and is advancing a planned cancer-therapy filing, but rising cost concerns and uncertain revenue visibility weighed on the shares heading into the weekend. The analyst consensus is Hold, with the supplied mean target 34% below Friday’s closing price.
When was the MRNA research last updated?
The most recent MRNA report was published on November 14, 2026.
What do analysts expect for MRNA?
As of November 1, 2026, the analyst consensus on MRNA is Hold (1 Strong Buy, 3 Buy, 16 Hold, 2 Sell, 2 Strong Sell). As of November 17, 2026, the analyst price target is $143.67 mean (range $25.00 to $305.00).
Is this MRNA research investment advice?
No. StockAlpha.ai research is AI-generated analysis for informational purposes only and is not investment advice. Analyst figures are third-party data. Do your own research before making investment decisions.
Keep exploring
- draft Moderna into a free practice contest: How to put the stock you just researched into a contest lineup at no real-money risk
- the healthcare sector brief for context on Moderna's peers: Today's sector-level news and moves around the stock